Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Open access
Short, K Detweiler, Rajkumar, S V, Larson, D, Buadi, F, Hayman, S, Dispenzieri, A, Gertz, M, Kumar, S, Mikhael, J, Roy, V, Kyle, R A, Lacy, M Q · 2011 · Leukemia

Abstract

We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2011.29

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 5

  1. Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962–2972. · DOI · Paper page
  2. Madan S, Kumar S . Review: extramedullary disease in multiple myeloma. Clin Adv Hematol Oncol 2009; 7: 802–804.
  3. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2009; 21: 325–330. · DOI · Paper page
  4. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas [see comment]. Br J Haematol 2001; 113: 422–424. · DOI
  5. Rosiñol L, Cibeira M, Bladé J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836.

Cited by

See all 209

Metadata

Authors
Short, K. D., Rajkumar, S. V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Gertz, M., Kumar, S., Mikhael, J., Roy, V, Kyle, R. A., & Lacy, M. Q.
Venue
Leukemia
Published
2011-02-25
Volume
25
Issue
6
Pages
906-908
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2057660602
Cited by
209
References
1
FWCI
8.49
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.